Artivion | CRY - Betriebsergebnis

Aktienkurs
35.29
Täglich Wechseln
-1.10 -3.02%
Monatlich
-8.46%
Jährlich
45.53%
Q1 Prognose
35.04




Betriebsergebnis Veränderung Datum
Abbott USD 2.25B 73M 2025-12
Accuray USD 4.71M 6.86M 2024-12
AngioDynamics USD -2.51M 5.41M 2025-09
Artivion USD 4.79M 6.85M 2025-12
AtriCure USD 2.49M 2.28M 2025-12
Baxter International USD -214.2M 415.4M 2025-12
Becton, Dickinson and Co. USD 663M 163M 2025-12
Boston Scientific USD 1.24B 203M 2025-12
Edwards Lifesciences USD 370.3M 54.8M 2025-12
Inogen USD -7.79M 728K 2024-09
Integra LifeSciences USD 66M 54.24M 2025-12
J&J USD 5.59B 1.81B 2025-12
Mesa Laboratories USD 5.78M 2.27M 2024-12
Orthofix International USD 6.12M 1.91M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
ResMed USD 497.6M 35.25M 2025-12
Stryker USD 1.97B 609M 2025-12
Surmodics USD -5.64M 276K 2024-09
Tandem Diabetes Care USD 8.29M 31.16M 2025-12
Teleflex USD 36.34M 445.24M 2025-12
Terumo JPY 43.88B 1.21B 2025-12
Trinity Biotech USD -509K 6.27M 2025-09